The global emergence of resistance in microbes in the hospital, as well as community settings, is posing a serious threat to the healthcare system.
Antimicrobial resistance (AMR) is defined as the ability of a microorganism to resist the adverse effect of a drug against which it was earlier susceptible. The non-judicial use, and over-the-counter sale of antibiotics, has led to the development of resistance in bacteria. They became resistant by developing various mechanisms such as expression of beta-lactamases, expression of a drug-efflux pump, alteration of the drug-targeted pathways, biofilm formation,
quorum sensing, etc. The problem is further augmented by the paucity of new antimicrobials/antibiotics in the market.
The traditional approach of developing new antimicrobials is time-consuming and non-economical. Hence, the utility of already available drugs/inhibitors for other diseases may serve as a good approach in looking forward to identify novel treatment options for infections caused by resistant microbes.
Antimicrobial resistance by itself is not a new phenomenon. It is rather an evolutionary process. The challenge is to develop new antimicrobials and employ new approaches to keep pace with ever-increasing AMR; or else we will find ourselves in the pre-antibiotic era. In silico approaches to identify novel molecules against AMR may put the process of drug discovery and design on a fast-track mode. Structural bioinformatics, high-throughput virtual screening, molecular docking, and molecular dynamics simulations approaches may eventually help to identify potential drug molecules. The structure-activity relationship (SAR) may further guide to develop even more potent drug molecules with minimal side effects.
Recently, several researchers have explored new ideas and strategies to advance the identification of active biomolecules which may act either alone or in combination with conventional antibiotics. To further explore the potential of novel antimicrobials, progressive research on its design and development is the need of the hour.
We aim to gather contributions from researchers in the field of antimicrobial drug design under In silico, In vitro, and In vivo perspectives. We hope to highlight the advances in employing molecular dynamics and molecular docking studies in conjunction with experimental techniques to identify antimicrobial drugs.
This Research Topic invites original research as well as review articles which may include, but are not limited to:
• Antibiotic resistance
• Antimicrobial peptides
• Drug discovery
• Anti-biofilm agents
• Anti-quorum sensing agents
• Bioactive compounds
• Bacteriophage therapy
• CRISPR/Cas
• Antimicrobial adjuvants
Articles submitted to this Research Topic will be encouraged to incorporate experimental data used to validate the ensued in silico predictions.
The global emergence of resistance in microbes in the hospital, as well as community settings, is posing a serious threat to the healthcare system.
Antimicrobial resistance (AMR) is defined as the ability of a microorganism to resist the adverse effect of a drug against which it was earlier susceptible. The non-judicial use, and over-the-counter sale of antibiotics, has led to the development of resistance in bacteria. They became resistant by developing various mechanisms such as expression of beta-lactamases, expression of a drug-efflux pump, alteration of the drug-targeted pathways, biofilm formation,
quorum sensing, etc. The problem is further augmented by the paucity of new antimicrobials/antibiotics in the market.
The traditional approach of developing new antimicrobials is time-consuming and non-economical. Hence, the utility of already available drugs/inhibitors for other diseases may serve as a good approach in looking forward to identify novel treatment options for infections caused by resistant microbes.
Antimicrobial resistance by itself is not a new phenomenon. It is rather an evolutionary process. The challenge is to develop new antimicrobials and employ new approaches to keep pace with ever-increasing AMR; or else we will find ourselves in the pre-antibiotic era. In silico approaches to identify novel molecules against AMR may put the process of drug discovery and design on a fast-track mode. Structural bioinformatics, high-throughput virtual screening, molecular docking, and molecular dynamics simulations approaches may eventually help to identify potential drug molecules. The structure-activity relationship (SAR) may further guide to develop even more potent drug molecules with minimal side effects.
Recently, several researchers have explored new ideas and strategies to advance the identification of active biomolecules which may act either alone or in combination with conventional antibiotics. To further explore the potential of novel antimicrobials, progressive research on its design and development is the need of the hour.
We aim to gather contributions from researchers in the field of antimicrobial drug design under In silico, In vitro, and In vivo perspectives. We hope to highlight the advances in employing molecular dynamics and molecular docking studies in conjunction with experimental techniques to identify antimicrobial drugs.
This Research Topic invites original research as well as review articles which may include, but are not limited to:
• Antibiotic resistance
• Antimicrobial peptides
• Drug discovery
• Anti-biofilm agents
• Anti-quorum sensing agents
• Bioactive compounds
• Bacteriophage therapy
• CRISPR/Cas
• Antimicrobial adjuvants
Articles submitted to this Research Topic will be encouraged to incorporate experimental data used to validate the ensued in silico predictions.